Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
TFF Pharmaceuticals Inc is a biotechnology business based in the US. TFF Pharmaceuticals shares (TFFP) are listed on the NASDAQ and all prices are listed in US Dollars. TFF Pharmaceuticals employs 4 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$7.71|
|52-week range||$6.85 - $21.14|
|50-day moving average||$7.72|
|200-day moving average||$9.35|
|Wall St. target price||$21.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.01|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||-3.38%|
|1 month (2021-09-27)||-5.98%|
|3 months (2021-07-27)||-8.76%|
|6 months (2021-04-27)||-33.19%|
|1 year (2020-10-26)||-46.38%|
|2 years (2019-10-25)||52.07%|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-37.66%|
|Return on equity TTM||-60.06%|
|Market capitalisation||$190.8 million|
TTM: trailing 12 months
There are currently 395,314 TFF Pharmaceuticals shares held short by investors – that's known as TFF Pharmaceuticals's "short interest". This figure is 11.3% up from 355,070 last month.
There are a few different ways that this level of interest in shorting TFF Pharmaceuticals shares can be evaluated.
TFF Pharmaceuticals's "short interest ratio" (SIR) is the quantity of TFF Pharmaceuticals shares currently shorted divided by the average quantity of TFF Pharmaceuticals shares traded daily (recently around 180508.67579909). TFF Pharmaceuticals's SIR currently stands at 2.19. In other words for every 100,000 TFF Pharmaceuticals shares traded daily on the market, roughly 2190 shares are currently held short.
However TFF Pharmaceuticals's short interest can also be evaluated against the total number of TFF Pharmaceuticals shares, or, against the total number of tradable TFF Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TFF Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 TFF Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0166% of the tradable shares (for every 100,000 tradable TFF Pharmaceuticals shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TFF Pharmaceuticals.
Find out more about how you can short TFF Pharmaceuticals stock.
We're not expecting TFF Pharmaceuticals to pay a dividend over the next 12 months.
TFF Pharmaceuticals, Inc. , an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in the Phase I clinical trials used for the prevention of lung transplant rejection. It is also developing other dry powder products, such as Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various types of pain; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.